Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology (HUST), 13 Hangkong Road, Wuhan, 430030, China.
Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, HUST, Wuhan, China.
J Nanobiotechnology. 2024 Aug 19;22(1):492. doi: 10.1186/s12951-024-02738-4.
BACKGROUND: Despite recent advances the prognosis of pulmonary hypertension remains poor and warrants novel therapeutic options. Extensive studies, including ours, have revealed that hypoxia-induced pulmonary hypertension is associated with high oxidative stress. Cerium oxide nanozyme or nanoparticles (CeNPs) have displayed catalytic activity mimicking both catalase and superoxide dismutase functions and have been widely used as an anti-oxidative stress approach. However, whether CeNPs can attenuate hypoxia-induced pulmonary vascular oxidative stress and pulmonary hypertension is unknown. RESULTS: In this study, we designed a new ceria nanozyme or nanoparticle (AuCeNPs) exhibiting enhanced enzyme activity. The AuCeNPs significantly blunted the increase of reactive oxygen species and intracellular calcium concentration while limiting proliferation of pulmonary artery smooth muscle cells and pulmonary vasoconstriction in a model of hypoxia-induced pulmonary hypertension. In addition, the inhalation of nebulized AuCeNPs, but not CeNPs, not only prevented but also blunted hypoxia-induced pulmonary hypertension in rats. The benefits of AuCeNPs were associated with limited increase of intracellular calcium concentration as well as enhancement of extracellular calcium-sensing receptor (CaSR) activity and expression in rat pulmonary artery smooth muscle cells. Nebulised AuCeNPs showed a favorable safety profile, systemic arterial pressure, liver and kidney function, plasma Ca level, and blood biochemical parameters were not affected. CONCLUSION: We conclude that AuCeNPs is an improved reactive oxygen species scavenger that effectively prevents and treats hypoxia-induced pulmonary hypertension.
背景:尽管最近取得了进展,但肺动脉高压的预后仍然很差,需要新的治疗选择。包括我们在内的广泛研究表明,缺氧性肺动脉高压与高氧化应激有关。氧化铈纳米酶或纳米颗粒(CeNPs)具有模仿过氧化氢酶和超氧化物歧化酶功能的催化活性,已被广泛用作抗氧化应激方法。然而,CeNPs 是否可以减轻缺氧诱导的肺血管氧化应激和肺动脉高压尚不清楚。
结果:在这项研究中,我们设计了一种新型的氧化铈纳米酶或纳米颗粒(AuCeNPs),具有增强的酶活性。AuCeNPs 显著减轻了活性氧和细胞内钙浓度的增加,同时限制了缺氧性肺动脉高压模型中肺动脉平滑肌细胞的增殖和肺血管收缩。此外,雾化吸入 AuCeNPs 不仅可以预防,而且可以减轻缺氧诱导的大鼠肺动脉高压。AuCeNPs 的益处与细胞内钙浓度的增加有限以及大鼠肺动脉平滑肌细胞中细胞外钙敏感受体(CaSR)活性和表达的增强有关。雾化吸入 AuCeNPs 具有良好的安全性,全身动脉压、肝功能、肾功能、血浆 Ca 水平和血液生化参数不受影响。
结论:我们得出结论,AuCeNPs 是一种改良的活性氧清除剂,可有效预防和治疗缺氧性肺动脉高压。
Antioxid Redox Signal. 2012-1-25
Pharmaceutics. 2025-2-10
Biomaterials. 2022-12
Eur Heart J. 2022-10-11
Circ Res. 2022-3-18